1 University of Toronto, Faculty of Medicine, Toronto, ON, Canada.
2 Skin Centre for Dermatology, Peterborough, ON, Canada.
J Cutan Med Surg. 2017 Nov/Dec;21(6):540-550. doi: 10.1177/1203475417716364. Epub 2017 Jun 22.
Anticoagulants are amongst the most commonly prescribed medications worldwide. Although rare, localised and systemic drug reactions have been reported with anticoagulants that can lead to significant morbidity and mortality. Some of the first signs of drug reactions to anticoagulants are cutaneous changes that, when recognised early, can prevent significant complications. Dermatologists should be aware of these changes to make an early and accurate diagnosis. This is particularly important in instances of skin-induced necrosis caused by systemic toxicity to anticoagulants. This review discusses adverse drug reactions to the traditional anticoagulants, warfarin and heparin, and the newer direct oral anticoagulants (DOACs) such as the thrombin inhibitor, dabigatran, and the factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban. In particular, this review provides dermatologists with a framework for early diagnosis and management of patients with drug reactions to anticoagulants and alerts them to potential bleeding complications associated with minor procedures.
抗凝剂是全球最常用的处方药物之一。尽管罕见,但已报道抗凝剂会引起局部和全身药物反应,从而导致严重的发病率和死亡率。抗凝剂药物反应的一些最初迹象是皮肤变化,如果及早发现,这些变化可以预防严重的并发症。皮肤科医生应该注意这些变化,以便及早做出准确的诊断。在由抗凝剂全身性毒性引起的皮肤坏死的情况下,这一点尤其重要。本文讨论了传统抗凝剂(华法林和肝素)和新型直接口服抗凝剂(DOACs)(如凝血酶抑制剂达比加群)以及因子 Xa 抑制剂利伐沙班、阿哌沙班和依度沙班)的药物不良反应。特别是,本文为皮肤科医生提供了一个框架,用于早期诊断和管理抗凝剂药物反应患者,并提醒他们注意与小手术相关的潜在出血并发症。